🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,061 results for “Bio” Clear

  1. Part 1: Cream

    BRIGHT MINDS BIOSCIENCES INC.

    Systemic Exposure to Sunscreen Ingredients

    phase 1 small molecule completed

    1 trial

  2. Pegfilgrastim

    Biotech Pharmaceutical Co.,

    Breast Cancer

    phase 1 small molecule completed

    1 trial

  3. Peginterferon lambda

    Biotech Pharmaceutical Co.,

    Hepatitis C

    phase 1 mab completed

    1 trial

  4. Pelareorep

    ONCOLYTICS BIOTECH INC

    Breast Cancer

    phase 1 mab terminated

    1 trial

  5. Peldesine

    Biocryst

    HIV Infections

    phase 1 small molecule completed

    1 trial

  6. Peptides (N,R&C) formulated in Montanide ISA 720

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria, Vivax

    phase 1 small molecule completed

    1 trial

  7. Perindopril

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 1 small molecule completed

    1 trial

  8. Pharmaceutical-lipid aspirin (PL-ASA)

    Protalix BioTherapeutics

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  9. Pharmacogenomics testing for clopidogrel responsiveness

    BRIGHT MINDS BIOSCIENCES INC.

    Stroke

    phase 1 other completed

    1 trial

  10. Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia A

    Swedish Orphan Biovitrum AB (publ)

    Haemophilia A

    phase 1 other active

    1 trial

  11. Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants

    Lacuna Pharma Pty Ltd

    Active psoriatic arthritis, Moderately to severely active Crohn’s disease, Moderate-to-severe plaque psoriasis, Moderately to severely active ulcerative colitis

    phase 1 other active

    1 trial

  12. Pharmacy-based methadone administration and dispensing

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 1 small molecule completed

    1 trial

  13. Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles

    Tyra Biosciences

    Locally Advanced Cholangiocarcinoma

    phase 1 small molecule active

    1 trial

  14. Phase 1 study on SAR443122 bioavailability and food effect in healthy adults

    Sanofi-aventis Healthcare Pty Ltd

    Colitis ulcerative

    phase 1 other active

    1 trial

  15. Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics

    GlaxoSmithKline

    Urinary Tract Infections

    phase 1 other active

    1 trial

  16. Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages

    BRIGHT MINDS BIOSCIENCES INC.

    Social Anxiety Disorder

    phase 1 other terminated

    1 trial

  17. Phase I-Ib clinical trial of safety and immunobiology of prophylactic infusion of lymphocytes and NK cells after Allo-HCT.

    The George Institute

    graft-versus-host disease

    phase 1 other active

    1 trial

  18. Phase I-Ib clinical trial of safety and immunobiology of prophylactic infusion of lymphocytes and NK cells after Allo-HCT.

    The George Institute

    graft-versus-host disease

    phase 1 other active

    1 trial

  19. Phenytoin

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 1 small molecule completed

    1 trial

  20. Piracetam

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 1 small molecule terminated

    2 trials

  21. Pirfenidone

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  22. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 1 small molecule active

    1 trial

  23. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 1 small molecule completed

    1 trial

  24. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 1 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources